↓ Skip to main content

Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?

Overview of attention for article published in European Neuropsychopharmacology, February 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter
11 X users

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
58 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Published in
European Neuropsychopharmacology, February 2022
DOI 10.1016/j.euroneuro.2022.02.004
Pubmed ID
Authors

Aiste Lengvenyte, Robertas Strumila, Emilie Olié, Philippe Courtet

X Demographics

X Demographics

The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 58 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 14%
Researcher 4 7%
Professor > Associate Professor 4 7%
Student > Doctoral Student 4 7%
Student > Master 4 7%
Other 9 16%
Unknown 25 43%
Readers by discipline Count As %
Medicine and Dentistry 10 17%
Psychology 5 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Neuroscience 4 7%
Unspecified 3 5%
Other 6 10%
Unknown 26 45%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2022.
All research outputs
#5,216,002
of 25,392,582 outputs
Outputs from European Neuropsychopharmacology
#501
of 2,574 outputs
Outputs of similar age
#115,771
of 451,532 outputs
Outputs of similar age from European Neuropsychopharmacology
#11
of 27 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,574 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,532 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.